Investor Presentaiton

SELECT TRIALS - JARDIANCE Study Indication* Title Phase Patients Primary Outcome* ** Lilly Primary Completion Completion NCT04509674 Myocardial Infarction EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) 3 6522 Composite of time to first heart failure hospitalisation or all-cause mortality Aug 2023 Aug 2023 In collaboration with Boehringer Ingelheim 1 Also lists Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead) * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use 2023 Q2 EARNINGS Source: clinicaltrials.gov, July 27, 2023 40 40

View entire presentation